Abstract:Background Cisplatin (CDDP)‐based chemotherapy has emerged as the primary treatment for muscle‐invasive bladder cancer and metastatic bladder cancer. Nevertheless, a significant proportion of patients experience rapidly developed chemoresistance, leading to treatment ineffectiveness. Existing evidence suggests that chemoresistance is governed by various factors, including tumor stem cells, epithelial mesenchymal transition, and reactive oxygen species (ROS). However, limited research has been conducted on the role of PRDX2, a crucial ROS scavenger, in the modulation of chemoresistance in bladder cancer. Methods Cisplatin‐resistant cell lines were established using the concentration gradient overlay method, and differentially expressed genes in resistant cells were screened through RNA sequencing. The expression of PRDX2 in cells and tissues was assessed using RT‐qPCR, Western Blot, and immunohistochemistry. The expression of PRDX2 in bladder cancer and adjacent tissues was evaluated using a bladder cancer tissue microarray. Furthermore, the impact of PRDX2 knockdown on tumor formation and metastasis was investigated in vivo by applying subcutaneous tumor xenografts tail vein metastasis assays. Results We demonstrated that PRDX2 is significantly upregulated in bladder tumors and cisplatin‐resistant bladder tumor cell lines. Overexpression of PRDX2 can promote tumor proliferation, migration, and invasion both in vitro and in vivo. We have found that knockdown of PRDX2 expression can effectively reverse cell resistance to cisplatin. Mechanistically, our findings suggest that PRDX2 is involved in regulating tumor stemness and epithelial‐mesenchymal transition (EMT). Knockdown of PRDX2 affects the PI3K‐AKT and mTOR signaling pathways, thereby influencing tumor stemness and EMT, ultimately impacting the chemotherapy resistance of the tumor. Conclusions This study provides a new insight into the regulation of chemotherapy resistance in bladder cancer by PRDX2. Targeting PRDX2 can serve as a potent therapeutic target for chemotherapy resistance.

LAMP2A regulates cisplatin resistance in colorectal cancer through mediating autophagy

Chloroquine Blocks The Autophagic Process In Cisplatin-Resistant Osteosarcoma Cells By Regulating The Expression Of P62/Sqstm1

LAMP2A overexpression in colorectal cancer promotes cell growth and glycolysis via chaperone‑mediated autophagy

Autophagy Facilitates Lung Adenocarcinoma Resistance to Cisplatin Treatment by Activation of AMPK/mTOR Signaling Pathway.

DDP Induced Cytotoxicity through miR-215-5p/COL5A1/FSTL1 Axis to Regulate Autophagy in Lung Adenocarcinoma Cells

Regulation of LC3-dependent protective autophagy in ovarian cancer cells by protein phosphatase 2A.

NPAS2 dampens chemo-sensitivity of lung adenocarcinoma cells by enhancing DNA damage repair

mTORC2-driven chromatin cGAS mediates chemoresistance through epigenetic reprogramming in colorectal cancer

Chaperone‐mediated autophagy affects tumor cell proliferation and cisplatin resistance in esophageal squamous cell carcinoma

Elucidating the role of CYFIP2 in conferring cisplatin resistance in esophageal squamous cell carcinoma

MicroRNA-199a-5p Inhibits Cisplatin-Induced Drug Resistance Via Inhibition of Autophagy in Osteosarcoma Cells.

Exploring the mechanism of cisplatin resistance by transcriptome sequencing and reversing the chemoresistance by autophagy inhibition in small cell lung cancer

Reregulated Mitochondrial Dysfunction Reverses Cisplatin Resistance Microenvironment in Colorectal Cancer

Upregulation of CRABP2 by TET1-mediated DNA Hydroxymethylation Attenuates Mitochondrial Apoptosis and Promotes Oxaliplatin Resistance in Gastric Cancer.

PrLZ Increases Prostate Cancer Docetaxel Resistance by Inhibiting LKB1/AMPK-mediated Autophagy.

Inhibition of Autophagy Improves Resistance and Enhances Sensitivity of Gastric Cancer Cells to Cisplatin.

Expression of LASS2 Can be Regulated by Dihydroartemisinin to Regulate Cisplatin Chemosensitivity in Bladder Cancer Cells

Chaperone-mediated autophagy receptor modulates tumor growth and chemoresistance in non-small cell lung cancer

PRDX2 regulates stemness contributing to cisplatin resistance and metastasis in bladder cancer

652 XPA Promotes Autophagy to Facilitate Cisplatin Resistance in Melanoma Cells Through the Activation of PARP1

PFKFB3 deprivation attenuates the cisplatin resistance via blocking its autophagic elimination in colorectal cancer cells